FDA Inspection 1315522 — Summit Therapeutics, Inc.
The FDA completed an inspection of Summit Therapeutics, Inc. on Apr 10, 2026 in Palo Alto, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 10, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Palo Alto, CA (United States)
Additional Details
Sponsor, Contract Research Organization